Your browser doesn't support javascript.
loading
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney, Sara M; Tarantino, Paolo; Graham, Noah; Tayob, Nabihah; Parè, Laia; Villacampa, Guillermo; Dang, Chau T; Yardley, Denise A; Moy, Beverly; Marcom, P Kelly; Albain, Kathy S; Rugo, Hope S; Ellis, Matthew J; Shapira, Iuliana; Wolff, Antonio C; Carey, Lisa A; Barroso-Sousa, Romualdo; Villagrasa, Patricia; DeMeo, Michelle; DiLullo, Molly; Zanudo, Jorge Gomez Tejeda; Weiss, Jakob; Wagle, Nikhil; Partridge, Ann H; Waks, Adrienne G; Hudis, Clifford A; Krop, Ian E; Burstein, Harold J; Prat, Aleix; Winer, Eric P.
Afiliação
  • Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: sara_tolaney@dfci.harvard.edu.
  • Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; European Institute of On
  • Graham N; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Tayob N; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Parè L; Reveal Genomics, Barcelona, Spain.
  • Villacampa G; Reveal Genomics, Barcelona, Spain.
  • Dang CT; Solid Tumor Division, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yardley DA; Department of Medical Oncology, Sarah Cannon Cancer Center, Nashville, TN, USA.
  • Moy B; Department of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Marcom PK; Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham, NC, USA.
  • Albain KS; Department of Medicine, Division of Hematology-Oncology, Loyola University Medical Center, Maywood, IL, USA.
  • Rugo HS; Department of Medicine, Division of Oncology, University of California, San Francisco, CA, USA.
  • Ellis MJ; Baylor Clinic Lester and Sue Smith Breast Center, Houston, TX, USA.
  • Shapira I; Regional Cancer Care Associates, New Hyde Park, New York, NY, USA.
  • Wolff AC; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
  • Carey LA; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Barroso-Sousa R; DASA Oncology, Brasilia Hospital, Diagnósticos da América SA (DASA), Brasília, Brazil.
  • Villagrasa P; Reveal Genomics, Barcelona, Spain.
  • DeMeo M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • DiLullo M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Zanudo JGT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Boston, MA, USA.
  • Weiss J; Broad Institute of MIT and Harvard, Boston, MA, USA.
  • Wagle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Boston, MA, USA.
  • Partridge AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Waks AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Hudis CA; Solid Tumor Division, Memorial Sloan Kettering Cancer Center, New York, NY, USA; American Society of Clinical Oncology, Alexandria, VA, USA.
  • Krop IE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Yale Cancer Center, New Haven, CT, USA.
  • Burstein HJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Prat A; Reveal Genomics, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain.
  • Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Yale Cancer Center, New Haven, CT, USA.
Lancet Oncol ; 24(3): 273-285, 2023 03.
Article em En | MEDLINE | ID: mdl-36858723
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article